산후 우울증 치료제 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 치료별, 투여 경로별, 유통 채널별, 지역별, 부문별 예측(2024-2030년)

Postpartum Depression Drugs Market Growth & Trends:

The global postpartum depression drugs market is anticipated to reach USD 1.59 billion by 2030 and is expected to expand at a CAGR of 9.63% during the forecast period, according to a new report by Grand View Research, Inc. The increasing number of pregnancies worldwide primarily drives market growth. Many women suffer from postpartum depression (PPD) after having a baby and are at high risk of developing major depression later in life. According to the Cleveland Clinic Estimate, postpartum depression is a common condition that affects 1 in 7 women after giving birth to a child. Thus, rising government support for women who had childbirth and are suffering from mood disorders like PDD is expected to boost demand for drugs over the forecast period.

According to the Indian Association of Preventive & Social Medicine, every year, around 30 million women experience pregnancy, and 27 million women have live childbirths. In July 2022, the Government of India launched several schemes to support pregnant women, such as Janani Suraksha Yojana (JSY) and Janani Shishu Suraksha Karyakaram (JSSK). Under these programs, the government offers free of cost treatment related to pregnancy, such as diagnostics, medicines, and other consumables. Thus, initiatives like JSSK and JSY support women in completing treatment such as postpartum depression, simultaneously driving market growth during the forecast period.

Another significant factor driving the adoption of postpartum depression drugs is rising healthcare expenditures, which help to improve infrastructure and improve patient access to healthcare facilities. According to the PETERSON-KFF Health System Tracker report, women spend around USD 18,865 annually on pregnancy, childbirth, and postpartum treatment. There is significant variation. around this, spending and costs vary significantly by region worldwide. The increasing access of women to PPD drug treatment is anticipated to drive market growth in the coming years.

Postpartum Depression Drugs Market Report Highlights:

• The postpartum anxiety segment held the largest share of the market in 2023. This can be attributed to the disease's high treatment rate and growing prevalence in developed and developing countries.
• Based on the treatment type, the hormonal therapy segment is expected to grow at the fastest CAGR during the forecast period.This can be attributed to the development and commercialization of new hormonal drugs and increased adoption by smaller hospitals and facilities for the treatment of PDD.
• In 2023, the oral segment held the largest share of the market based on the route of administration. This dominance can be attributed to the increase in the prevalence and incidence of disease worldwide, the large availability of products, and the rising demand for new generic oral drugs for treatment.
• The hospital pharmacy segment held the largest share of the market based on distribution channels in 2023. Hospital treatment rates, patient preference for hospitals over other healthcare settings for PDD treatment, and the increasing number of patients visiting hospitals.
• North America dominated the market owing to factors such as advanced healthcare infrastructure, rising disease prevalence, and favorable regulatory environment.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Treatment
  • 1.2.3. Route of Administration
  • 1.2.4. Distribution Channel
  • 1.2.5. Regional scope
  • 1.2.6. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Treatment and Treatment outlook
  • 2.2.2. Route of Administration outlook
  • 2.2.3. Distribution Channel and Availability outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Postpartum Depression Drugs Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing prevalence of postpartum depression
    • 3.2.1.2. Advancements in drug development
    • 3.2.1.3. Growing awareness and diagnosis
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost of treatment
    • 3.2.2.2. Regulatory challenges for new drug approvals
• 3.3. Postpartum Depression Drugs Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's Five Forces
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
  • 3.3.3. Pipeline Analysis

Chapter 4. Postpartum Depression Drugs Market: Treatment Estimates & Trend Analysis

• 4.1. Global Postpartum Depression Drugs Market: Type Dashboard
• 4.2. Global Postpartum Depression Drugs Market: Type Movement Analysis
• 4.3. Global Postpartum Depression Drugs Market by Treatment, Revenue
• 4.4. Postpartum Blues
  • 4.4.1. Postpartum blues market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Postpartum Anxiety
  • 4.5.1. Postpartum anxiety market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Postpartum Obsessive-Compulsive Disorder (OCD)
  • 4.6.1. Postpartum obsessive-compulsive disorder (OCD) market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Postpartum Post-Traumatic Stress Disorder (PTSD)
  • 4.7.1. Postpartum post-traumatic stress disorder (PTSD) market estimates and forecasts 2018 to 2030 (USD Million)
• 4.8. Postpartum Panic Disorder
  • 4.8.1. Postpartum panic disorder market estimates and forecasts 2018 to 2030 (USD Million)
• 4.9. Preventive
  • 4.9.1. Postpartum psychosis market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Postpartum Depression Drugs Market: Treatment Estimates & Trend Analysis

• 5.1. Global Postpartum Depression Drugs Market: Treatment Dashboard
• 5.2. Global Postpartum Depression Drugs Market: Treatment Movement Analysis
• 5.3. Global Postpartum Depression Drugs Market Estimates and Forecasts, By Treatment, Revenue (USD Million)
• 5.4. Pharmacotherapy
  • 5.4.1. Pharmacotherapy market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Hormonal Therapy
  • 5.5.1. Hormonal therapy market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Others
  • 5.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Postpartum Depression Drugs Market: Route of Administration Estimates & Trend Analysis

• 6.1. Global Postpartum Depression Drugs Market: Route of Administration Dashboard
• 6.2. Global Postpartum Depression Drugs Market: Route of Administration Movement Analysis
• 6.3. Global Postpartum Depression Drugs Market Estimates and Forecasts, by Route of Administration, Revenue (USD Million)
• 6.4. Parenteral
  • 6.4.1. Parenteral market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Oral
  • 6.5.1. Oral market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Others
  • 6.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Postpartum Depression Drugs Market: Distribution Channel Estimates & Trend Analysis

• 7.1. Global Postpartum Depression Drugs Market: Distribution Channel Dashboard
• 7.2. Global Postpartum Depression Drugs Market: Distribution Channel Movement Analysis
• 7.3. Global Postpartum Depression Drugs Market Estimates and Forecasts by Distribution Channel, Revenue (USD Million)
• 7.4. Hospital Pharmacy
  • 7.4.1. Hospital pharmacy market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Retail Pharmacy
  • 7.5.1. Retail pharmacy market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Others (Online Pharmacy)
  • 7.6.1. Others (online pharmacy) market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Postpartum Depression Drugs Market: Regional Estimates & Trend Analysis by Treatment, Therapeutic Class, and Route of Administration

• 8.1. Regional Dashboard
• 8.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 8.3. North America
  • 8.3.1. U.S.
    • 8.3.1.1. Key country dynamics
    • 8.3.1.2. Regulatory framework/ reimbursement structure
    • 8.3.1.3. Competitive scenario
    • 8.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.3.2. Canada
    • 8.3.2.1. Key country dynamics
    • 8.3.2.2. Regulatory framework/ reimbursement structure
    • 8.3.2.3. Competitive scenario
    • 8.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.3.3. Mexico
    • 8.3.3.1. Key country dynamics
    • 8.3.3.2. Regulatory framework/ reimbursement structure
    • 8.3.3.3. Competitive scenario
    • 8.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 8.4. Europe
  • 8.4.1. UK
    • 8.4.1.1. Key country dynamics
    • 8.4.1.2. Regulatory framework/ reimbursement structure
    • 8.4.1.3. Competitive scenario
    • 8.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.2. Germany
    • 8.4.2.1. Key country dynamics
    • 8.4.2.2. Regulatory framework/ reimbursement structure
    • 8.4.2.3. Competitive scenario
    • 8.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.3. France
    • 8.4.3.1. Key country dynamics
    • 8.4.3.2. Regulatory framework/ reimbursement structure
    • 8.4.3.3. Competitive scenario
    • 8.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.4. Italy
    • 8.4.4.1. Key country dynamics
    • 8.4.4.2. Regulatory framework/ reimbursement structure
    • 8.4.4.3. Competitive scenario
    • 8.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.5. Spain
    • 8.4.5.1. Key country dynamics
    • 8.4.5.2. Regulatory framework/ reimbursement structure
    • 8.4.5.3. Competitive scenario
    • 8.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.6. Norway
    • 8.4.6.1. Key country dynamics
    • 8.4.6.2. Regulatory framework/ reimbursement structure
    • 8.4.6.3. Competitive scenario
    • 8.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.7. Sweden
    • 8.4.7.1. Key country dynamics
    • 8.4.7.2. Regulatory framework/ reimbursement structure
    • 8.4.7.3. Competitive scenario
    • 8.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.8. Denmark
    • 8.4.8.1. Key country dynamics
    • 8.4.8.2. Regulatory framework/ reimbursement structure
    • 8.4.8.3. Competitive scenario
    • 8.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. Japan
    • 8.5.1.1. Key country dynamics
    • 8.5.1.2. Regulatory framework/ reimbursement structure
    • 8.5.1.3. Competitive scenario
    • 8.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.2. China
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework/ reimbursement structure
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.3. India
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework/ reimbursement structure
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.4. Australia
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Regulatory framework/ reimbursement structure
    • 8.5.4.3. Competitive scenario
    • 8.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.5. South Korea
    • 8.5.5.1. Key country dynamics
    • 8.5.5.2. Regulatory framework/ reimbursement structure
    • 8.5.5.3. Competitive scenario
    • 8.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.6. Thailand
    • 8.5.6.1. Key country dynamics
    • 8.5.6.2. Regulatory framework/ reimbursement structure
    • 8.5.6.3. Competitive scenario
    • 8.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 8.6. Latin America
  • 8.6.1. Brazil
    • 8.6.1.1. Key country dynamics
    • 8.6.1.2. Regulatory framework/ reimbursement structure
    • 8.6.1.3. Competitive scenario
    • 8.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.2. Argentina
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework/ reimbursement structure
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 8.7. MEA
  • 8.7.1. South Africa
    • 8.7.1.1. Key country dynamics
    • 8.7.1.2. Regulatory framework/ reimbursement structure
    • 8.7.1.3. Competitive scenario
    • 8.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.2. Saudi Arabia
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework/ reimbursement structure
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.3. UAE
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework/ reimbursement structure
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.4. Kuwait
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory framework/ reimbursement structure
    • 8.7.4.3. Competitive scenario
    • 8.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company/Competition Categorization
• 9.2. Vendor Landscape
  • 9.2.1. List of key distributors and channel partners
  • 9.2.2. Key customers
  • 9.2.3. Key company market share analysis, 2023
  • 9.2.4. Sage Therapeutics, Inc.
    • 9.2.4.1. Company overview
    • 9.2.4.2. Financial performance
    • 9.2.4.3. Product benchmarking
    • 9.2.4.4. Strategic initiatives
  • 9.2.5. Pfizer Inc.
    • 9.2.5.1. Company overview
    • 9.2.5.2. Financial performance
    • 9.2.5.3. Product benchmarking
    • 9.2.5.4. Strategic initiatives
  • 9.2.6. Eli Lilly and Company.
    • 9.2.6.1. Company overview
    • 9.2.6.2. Financial performance
    • 9.2.6.3. Product benchmarking
    • 9.2.6.4. Strategic initiatives
  • 9.2.7. GSK plc
    • 9.2.7.1. Company overview
    • 9.2.7.2. Financial performance
    • 9.2.7.3. Product benchmarking
    • 9.2.7.4. Strategic initiatives
  • 9.2.8. Merck & Co., Inc.
    • 9.2.8.1. Company overview
    • 9.2.8.2. Financial performance
    • 9.2.8.3. Product benchmarking
    • 9.2.8.4. Strategic initiatives
  • 9.2.9. Biogen Inc.
    • 9.2.9.1. Company overview
    • 9.2.9.2. Financial performance
    • 9.2.9.3. Product benchmarking
    • 9.2.9.4. Strategic initiatives
  • 9.2.10. Bausch Health Companies Inc.
    • 9.2.10.1. Company overview
    • 9.2.10.2. Financial performance
    • 9.2.10.3. Product benchmarking
    • 9.2.10.4. Strategic initiatives
  • 9.2.11. Cipla Inc.
    • 9.2.11.1. Company overview
    • 9.2.11.2. Financial performance
    • 9.2.11.3. Product benchmarking
    • 9.2.11.4. Strategic initiatives
  • 9.2.12. Novartis AG.
    • 9.2.12.1. Company overview
    • 9.2.12.2. Financial performance
    • 9.2.12.3. Product benchmarking
    • 9.2.12.4. Strategic initiatives
  • 9.2.13. Teva Pharmaceutical Industries Ltd.
    • 9.2.13.1. Company overview
    • 9.2.13.2. Financial performance
    • 9.2.13.3. Product benchmarking
    • 9.2.13.4. Strategic initiatives